Sangamo Biosciences, Inc. - SGMO- Profile

Sangamo Biosciences, Inc.. The Group's principal activities are to conduct research, develop and commercialization of DNA binding proteins for the therapeutic regulation and modification of disease-associated genes. The Group's gene recognition-TM- technology platform is a proprietary technology enabling the engineering of a class of transcription factors known as Zinc finger DNA-binding proteins (ZFPs). Universal gene recognition enables the technology, which is widely applicable to pharmaceutical discovery, development of human therapeutics, clinical diagnostics and plant agricultural and industrial biotechnology. The Group intends to commercialize its technology on its applications. The Group operates only in domestic market. The Group acquired clinical-stage ZFP TF therapeutic angiogenesis program from Edwards Lifesciences LLC (Edwards) in Dec 2006. Collaboration Agreements accounted for 84% of 2006 revenues and Federal Government Research Grants, 16%